Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
22 hedge funds and large institutions have $404K invested in Statera Biopharma, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
12% less funds holding
Funds holding: 25 → 22 (-3)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
37% less capital invested
Capital invested by funds: $645K → $404K (-$241K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$368K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.41K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.68K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$518 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$188 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$20.3K |
| 2 |
Walleye Trading
New York
|
-$10K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$3K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.68K |
STAB Hedge Fund Activity: Q1 2016 in Review
22 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2016, worth a combined $404K — down 37% from $645K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of STAB and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Cowen Inc, opening a new position worth an estimated $368K. The largest seller was Virtu KCG Holdings, cutting an estimated $20.3K.
- 22 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2016, down from 25 in Q4 2015.
- Funds reported $404K of Statera Biopharma, Inc. Common Stock stock for Q1 2016, down 37% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q1 2016 and 4 closed out, a net change of -3 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2016 was Cowen Inc, an estimated $368K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2016 was Virtu KCG Holdings, an estimated $20.3K sold.
Based on aggregated 13F filings for Q1 2016.